Clinical Cancer Treatment and Drug Resistance: The Interface of the Clinic and the Laboratory

  • Eddie Reed
  • Bruce A. Chabner


The development of drug resistance is a major roadblock to successful systemic cancer therapy. Although much research has been devoted to this subject in recent years, these efforts have been focused primarily on the molecular mechanisms operative in resistance to chemotherapy. Older, traditional approaches to drug resistance developed from a knowledge of clinical factors such as “sanctuary sites” of metastatic disease and stemmed from empirical observations relating tumor bulk to the likelihood of successful therapy. These observations led to the use of intrathecal chemotherapy for diseases metastatic to the central nervous system, to experimentation with intraperitoneal chemotherapy, and to several theories relating tumor size to chemotherapeutic efficacy. Little attention has been given to the interplay of molecular factors and clinical factors in the development of drug resistance in patients receiving systemic cancer treatment. In this volume we seek to give an overview of known molecular and clinical factors which may result in cancer drug resistance and the probable interplay of these factors in the evolution of resistance in man. Finally, we discuss treatment approaches that hold promise for overcoming the hurdles that exist between current technological possibilities and practical aspects of achieving cancer cure.


Ovarian Cancer Intraperitoneal Chemotherapy Human Ovarian Cancer Cell Human Ovarian Carcinoma Cell Pleiotropic Drug Resistance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G. A. Curt, N. J. Clendeninn, and B. A. Chabner, Drug Resistance in Cancer, Cancer Treat. Rep. 68: 87 (1984).PubMedGoogle Scholar
  2. 2.
    R. T. Schimke, Gene Amplification and Drug Resistance, Sci. Am. 243: 60 (1980).PubMedCrossRefGoogle Scholar
  3. 3.
    B. A. Chabner, G. A. Curt, and R. L. Fine, Implications of Drug Resistance for Cancer Drug Development, Proc. Am. Assoc. Cancer Res. 26: 390 (1985).Google Scholar
  4. 4.
    J. Jolivet, K. H. Cowan, G. A. Curt, N. J. Clendeninn, and B. A. Chabner, The Pharmacology and Clinical Use of Methotrexate, N. Eng. J. Med. 309: 1094 (1983).CrossRefGoogle Scholar
  5. 5.
    R. Tram, P. Cusick, J. Wilson, and M. Merinus, Mismatch Repair of cis-Diamminedichloroplatinum II (CDDP) Induced DNA Damage in E. cola, Abstracts, Proc. 4th Internatl. Conf. on Environmental Mutagens (1985).Google Scholar
  6. 6.
    E. Reed, B. Behrens, S. H. Yuspa, M. C. Poirier, T. Hamilton, and R. F. Ozols, Differences in Cisplatin-DNA Adduct Formation in Sensitive and Resistant Sublines of Human Ovarian Cancer Cells, Proc. Am. Assoc. Cancer Res., submitted for publication (1986).Google Scholar
  7. 7.
    V. Bianchi, Nucleotide Pool Unbalance Induced in Cultured Cells by Treatments with Different Chemicals, Toxicology 25: 13 (1982).PubMedCrossRefGoogle Scholar
  8. 8.
    G. C. Walker, Inducible DNA Repair Systems, Ann. Rev. Biochem. 54: 425 (1985).PubMedCrossRefGoogle Scholar
  9. 9.
    L. Endresen, L. Schjernen, and H. Rugstad, Tumors from a Cell Strain with a High Content of Metallothionein Show Enhanced Resistance against cis-Dichlorodiammineplatinum, Acta. Pharmacol. Toxicol. 55: 183 (1984).CrossRefGoogle Scholar
  10. 10.
    T. C. Hamilton, M. A. Winker, K. G. Louie, G. Batist, B. C. Behrens, T. Tsuruo, K. R. Grotzinger, W. M. McKay, R. C. Young, and R. F. Ozols, Augmentation of Adriamycin, Melphalan, and Cisplatin Cytotoxicity in Drug-resistant and -sensitive Human Ovarian Carcinoma Cell Lines by Buthionine and Sulfoxamine Mediated Glutathione Depletion, Biochem. Pharm. 34: 2583 (1985).PubMedCrossRefGoogle Scholar
  11. 11.
    T. C. Hamilton, R. C. Young, W. M. McKoy, K. R. Grotzinger, J. A. Green, E. W. Chu, J. Whang-Peng, A. M. Rogan, W. R. Green, R. F. Ozols, Characterization of a Human Ovarian Carcinoma Cell Line (NIH: OVCAR-3) with Androgen and Estrogen Receptors, Cancer Res. 43: 5379 (1983).PubMedGoogle Scholar
  12. 12.
    D. R. Bell, J. H. Gerlach, N. Kartner, R. N. Burk, and V. Ling, Detection of P-glycoprotein in Ovarian Cancer: A Molecular Marker Associated with Multidrug Resistance, J. Clin. Oncol. 3: 311 (1985).PubMedGoogle Scholar
  13. 13.
    A. T. Fojo, J. Whang-Peng, M. M. Gottesman, and I. Pastan, Amplification of DNA Sequences in Human Multidrug-resistant KB Carcinoma Cells, Proc. Natl. Acad. Sci. U.S.A. 82: 7661 (1985).PubMedCrossRefGoogle Scholar
  14. 14.
    T. Tsuruo, H. Iida, S. Tsukagoshi, and Y. Sakurai, Potentiation of Vincristine and Adriamycin Effects in Human Hemopoietic Tumor Cell Lines by Calcium Antagonists and Calmodulin Inhibitors, Cancer Res. 43: 2267 (1983).PubMedGoogle Scholar
  15. 15.
    S. N. Roy and S. B. Horowitz, A Phosphoglycoprotein Associated with Taxol Resistance in J774.2 Cells, Cancer Res. 45: 3856 (1985).PubMedGoogle Scholar
  16. 16.
    J. H. Goldie and A. J. Coldman, The Genetic Origin of Drug Resistance in Neoplasms: Implications for Systemic Therapy, Cancer Res. 44: 3643 (1984).PubMedGoogle Scholar
  17. 17.
    E. Frei and G. P. Canellos, Dose: A Critical Factor in Cancer Chemotherapy, Am. J. Med. 69: 585 (1980).PubMedCrossRefGoogle Scholar
  18. 18.
    W. Hryniuk and H. Bush, The Importance of Dose Intensity in Chemotherapy of Metastatic Breast Cancer, J. Clin. Oncol. 2: 1281 (1984).PubMedGoogle Scholar
  19. 19.
    C. B. Pratt, A. Hayes, A. A. Green, W. E. Evans, N. Senzer, C. B. Howarth, J. L. Ransom, and W. Crom, Pharmacokinetic Evaluation of Cisplatin in Children with Malignant Solid Tumors: A Phase II Study, Cancer Treat. Rep. 65: 1021 (1981).PubMedGoogle Scholar
  20. 20.
    C. Myers, The Use of Intraperitoneal Chemotherapy in the Treatment of Ovarian Cancer, Semin. Oncol. 11: 275 (1984).PubMedGoogle Scholar
  21. 21.
    R. F. Ozols and R. C. Young, Patterns of Failure of Chemotherapy in Gynecologic Malignancy: Implications for Future Clinical Trials, Cancer Treat. Symposia 2: 233 (1983).Google Scholar
  22. 22.
    P. L. Kornblith, M. D. Walker, and J. R. Cassady, Treatment of Metastatic Cancer to Brain, in: “Cancer: Principles and Practice of Oncology,” V. T. DeVita, S. Hellman, and S. A. Rosenberg, eds., Lippincott, Philadelphia, (1985).Google Scholar
  23. 23.
    D. G. Poplack, J. R. Cassady, and P. A. Pizzo, Leukemias and Lymphomas of Childhood, in: “Cancer: Principles and Practice of Oncology,” V. T. DeVita, S. Hellman, and S. A. Rosenberg, eds., Lippincott, Philadelphia, (1985).Google Scholar
  24. 24.
    E. Reed, S. H. Yuspa, L. A. Zwelling, R. F. Ozols, and M. C. Poirier, Quantitation of cis-Diamminedichloroplatinum II (cisplatin)-DNAIntrastrand Adducts in Testicular and Ovarian Cancer Patients Receiving Cisplatin Chemotherapy, J. Clin. Invest., in press (1986).Google Scholar
  25. 25.
    J. R. Quesada, J. Reuben, J. T. Manning, E. M. Hersh, and J. U. Gutterman, Alpha Interferon for Induction in Hairy Cell Leukemia, N. Eng. J. Med. 310: 15 (1984).CrossRefGoogle Scholar
  26. 26.
    S. A. Rosenberg, M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chong, S. E. Ettinghausen, Y. L. Matory, J. M. Skibber, E. Shiloni, J. T. Vetto, C. A. Seipp, C. Simpson, and C. M. Reichert, Observations on the Systemic Administration of Autologous Lymphokine-activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer, N. Eng. J. Med. 313: 1485 (1985).CrossRefGoogle Scholar
  27. 27.
    R. H. Wiltrout and R. R. Salup, Combined Modality Approach to Treatment of Murine Renal Cancer, in: “Proceedings of the Congress on Natural Immunity and Therapy of Cancer and Other Diseases,” E. Lotzova, ed., S. Karger, A.G. Basel, in press (1986).Google Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Eddie Reed
    • 1
  • Bruce A. Chabner
    • 1
  1. 1.Division of Cancer TreatmentNational Cancer InstituteBethesdaUSA

Personalised recommendations